ThomasWFlaigMD

Genitourinary Oncology, Hematologic Oncology

Professor, Medicine, University of Colorado School of Medicine and Vice Chancellor for Research, CU Anschutz Medical Campus

Request Appointment

Overview of Dr. Flaig

Dr. Thomas Flaig is an oncologist in Aurora, CO and is affiliated with University of Colorado Hospital. He received his medical degree from University of Minnesota Medical School and has been in practice 18 years. Dr. Flaig accepts several types of health insurance, listed below. He is one of 127 doctors at University of Colorado Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
1665 Aurora Ct
1st Floor
Aurora, CO 80045
Book by Phone+1(720) 702-8055

Fax+1 720-848-0180

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2003 - 2006
Hennepin HealthcareResidency, Internal Medicine, 1999 - 2003
University of Minnesota Medical SchoolClass of 1999
St. John's University BA, Natural Science , 1991 - 1995

Certifications & Licensure

CO State Medical License 2006 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Jul 01
Completed
Phase 2
The Effect of Treatment on Circulating Tumor Cells in Bladder Cancer Patients With Muscle-invasive or Advanced Disease Start of enrollment: 2008 Nov 01
Completed
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy Start of enrollment: 2011 Aug 09
Active, not recruiting
Phase 2
Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma Start of enrollment: 2014 Feb 01
Withdrawn
Phase 2
S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer Start of enrollment: 2014 Aug 28
Completed
Phase 2
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

3286 citations
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher, Karim Fizazi, Fred Saad, Mary-Ellen Taplin, Cora N. Sternberg
The New England Journal of Medicine. 2012-09-26
8 citations
Collision renal cell papillary and medullary carcinoma in a 66-year-old man.
Elaine T. Lam, Elizabeth R. Kessler, Thomas W. Flaig, Francisco G. La Rosa
Oncology. 2013-09-16
102 citations
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen
Journal of Clinical Oncology. 2023-01-01

Lectures

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Podcast: CU Anschutz Powers up for Regenerative Medicine FrontierMay 9th, 2023
A New Way to Conduct Research: Streamlining the Clinical TrialApril 12th, 2023
Criterium, Inc. Announces Formation of New Oncology Research Consortium for Genito-Urinary IndicationsJanuary 26th, 2023
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois BlueChoice Select
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
First Health PPO
Great West PPO
HealthLink PPO
Humana ChoiceCare Network PPO
Kaiser Permanente
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment